Complement C5a as the Dominant NLRP3 Priming Signal in Gout¶

Chokepoint 0 in the NLRP3 exploit map. This deep dive documents the evidence that gout priming is complement-dominant rather than LPS-dominant, maps the therapeutic landscape at this under-exploited step, and tracks the Open Enzyme platform's CP0 coverage status.

CP0 status update (2026-05-05): what the wiki long named the "honest platform gap" — the only chokepoint with zero fermentable coverage, defaulting to avacopan as a permanent pharma adjunct — has shifted in this single working session from "platform gap" to "in silico-validated fermentable engineering candidate, with three known wet-lab unknowns." The trace: §1.21 (2026-04-27 computational scan of natural-product C5aR1 antagonists) closed the small-molecule angle definitively. Then 2026-05-05: scoped engineered soluble complement regulators (sCR1 / Factor H / DAF/CD55) as a peer-track exploration vector → comp-006 found the full DAF/CD55 ectodomain HIGH protease risk in shio-koji (driven by the disordered Ser/Thr stalk, aa 286–353) → the 2026-05-05 sweep daemon's Pass 2 surfaced a stalk-truncated SCR1-4 hypothesis as a wet-lab proposal → comp-012 verified in silico: SCR1-4 truncated DAF/CD55 (aa 35–285) is LOW protease risk (max 0.039, identical to uricase). The truncation removed 100% of exposed sites (9 NPr + 48 ALP + 1 acid_protease all gone); SCR1-4 is well-folded with all internal recognition sites buried.

C5aR1 platform gap confirmed empirically by comp-014 (2026-05-06): The comp-014 medicinal mushroom compound × chokepoint mapping Phase 2 breadth aggregation (6,798 fungal compounds across ChEMBL + LOTUS + PubMed) independently confirmed the §1.21 finding — zero direct fungal C5aR1 antagonists exist in either ChEMBL or PubMed. The gap is now confirmed by two independent computational scans (ChEMBL/NPASS/LOTUS/Open Targets §1.21 + fungal-breadth comp-014), strengthening the conclusion that natural-product CP0 coverage is structurally absent. (Mechanistic Extrapolation; source: medicinal-mushroom-compound-mapping-computational.md)

Upstream-CP0 dietary axis newly active per comp-018 (2026-05-08): The comp-018 upstream complement modulator sweep executed across all compound classes (not just fungal) triply re-confirms C5aR1 emptiness (ChEMBL + PubMed + cross-class scan) but uncovers a substantial natural-product literature one node upstream at the C3 convertase. Anchor: rosmarinic acid (rosemary, lemon balm, spearmint, salvia, mentha) — C3-convertase IC50 5-10 µM optimal (Englberger 1988 PMID 3198307), three independent in vivo precedents (rat CVF lung injury, Pkd1-/- mouse + rat ADPKD, classical paw oedema). FDA GRAS source plants. Dietary-tier dosable. ⚠️ Assay-format spread caveat (added 2026-05-14): the 5–10 µM Englberger 1988 number is the lower bound of a 20–30× IC50 spread; downstream alternate-assay setups (Cimanga 1999, Mu 2013) report 137–182 µM for the same compound. Neither value has been full-text grep-verified; both are abstract-tier. The lower-bound number should not be used as a load-bearing input to a dietary CP0 recommendation or wet-lab gate until the assay-format mapping resolves the spread. Resolution path: comp-021 in computational-experiments.md §Planned Analyses (compound × upstream-complement chokepoint × matched-assay-format mapping); discussion at upstream-complement-verification-rerun-computational.md §3.3. Per comp-018: the chokepoint-hacker move worked — don't fight at C5aR1, prevent C5a from being generated. Luteolin gains a third gout mechanism (CP+AP convertase CH50 190 µM / AP50 170 µM, Zhang & Chen 2008 PMID 18400428) on top of comp-013's XO + URAT1 evidence — highest-leverage single dietary compound in the OE corpus. Bupleurum polysaccharides (Chai Hu, TCM) inhibit lectin pathway IC50 ~1 mg/mL (Wu 2015 PMID 26579461) — gut-luminal viable, mechanistically orthogonal to RMA + luteolin. Two engineering parallel threads surfaced: recombinant C1-INH expression as near-twin to H05 DAF SCR1-4 (FDA-approved precedent: Berinert / Ruconest), and bacterial NRPS complestatin-family BGC heterologous expression in the LBP chassis peer track. Chokepoint-class naming proposed as scope-expansion of CP0 ("upstream-CP0") rather than new CP-1 class — decision deferred to user. (Sources: etc/experiments/comp-018-upstream-complement-modulator-sweep/, upstream-complement-modulator-sweep-computational.md)

Three known unknowns before CP0 can be called "closed": (1) does the truncated construct actually fold correctly with all 8 disulfide bonds (2 per SCR domain × 4 SCRs, per UniProt P08174 — corrected from earlier hallucinated estimate of 12 per comp-012 §1.5 correction note 2026-05-06) when expressed in A. oryzae? (2) does the soluble truncated fragment retain CCP-regulatory function (C3b/C4b binding + decay-accelerating activity)? (3) does luminal-side DAF actually engage submucosal-macrophage CP0 priming, or only act at the mucus interface? Each is a real wet-lab gating question; none individually fatal but cumulatively they could derail the closure thesis. Wet-lab plan formalized 2026-05-06 as validation-experiments.md §1.25: clone SCR1-4 (aa 35–285) with koji-native α-amylase signal peptide, express in A. oryzae RIB40 (NSlD-ΔP10 unlikely needed for single-cassette per chaperone framework refinement — effective PDI load 2.4-4.8 vs. demonstrated capacity of 16), assess secretion + disulfide folding by SDS-PAGE + mass spec, then functional CCP-regulatory activity in zymosan-activation C5a-generation inhibition assay. Estimated $2.5-4K, 6-8 weeks. Single-cassette routing, NOT triple-cassette — per the chaperone framework's triple-cassette prediction (architecture-refined 2026-05-06) landing below the 0.6 decision gate, DAF SCR1-4 should be either a sister-strain co-fermented with the uricase + Lf endgame, OR a payload candidate for the LBP chassis peer track if reject outcome. The platform's CP0 coverage status has moved from "pharma-only, document the honest gap" to "active engineering candidate with a formalized wet-lab plan and explicit single-cassette routing rationale."

Falsification card: queued as wiki/hypotheses/H05-daf-scr14-cp0-thesis.md (stub-level for now, full population queued as a follow-up Phase 2 item once wet-lab access is confirmed).

Scope: mechanism primer (complement cascade → crystal activation → C5a → priming), receptor biology (C5aR1 / C5aR2 / C3aR), cell-type effects in gout flares, genetics, the full therapeutic landscape (approved drugs, research compounds, natural products), combination biology versus LPS priming, Open Enzyme strategy, clinical biomarkers, and open research questions.

1. Complement Cascade Primer¶

Complement is the soluble effector arm of innate immunity — a self-assembling proteolytic cascade of ~30 proteins that opsonizes pathogens, recruits phagocytes, and lyses membranes. It is old (evolved before adaptive immunity), fast (seconds-to-minutes kinetics), and dangerously promiscuous when mis-regulated. Gout exploits it.

Three activation pathways, one convergence point¶

Classical         Lectin           Alternative
  |                 |                  |
  C1q binds        MBL binds         "Tick-over" +
  IgM/IgG          carbohydrates     surface C3b
  or charged       (fungal mannose,  deposition
  surfaces         bacterial)
  |                 |                  |
  C1r/s             MASP-1/2           Factor B +
  |                 |                  Factor D
  ▼                 ▼                  ▼
  C4 + C2 → C4b2a (classical/lectin C3 convertase)
                      \      |      /
                       \     |     /
                   C3b deposits, amplifies via
                   alternative pathway (C3bBb)
                              |
                              ▼
                    C5 convertase (C4b2a3b or C3bBbC3b)
                              |
                ┌─────────────┼─────────────┐
                ▼             ▼             ▼
              C5a            C5b ──► C5b-9 (MAC)
         (anaphylatoxin)         (pore on target membrane)

        Opsonization:    C3b, iC3b
        Anaphylatoxins:  C3a, C5a
        Lytic effector:  C5b-9 (MAC)

Classical pathway. Triggered by C1q binding to IgM or clustered IgG Fc on a target surface, or by direct binding to charged surfaces (including MSU crystals — see §2). C1q binding activates C1r and C1s, which cleave C4 and C2 to form the C4b2a C3 convertase.
Lectin pathway. Triggered by mannose-binding lectin (MBL) or ficolins recognizing microbial carbohydrate patterns, activating MASP-1 and MASP-2 (analogs of C1r/s). Converges on the same C4b2a convertase.
Alternative pathway. Constitutively idling via spontaneous "tick-over" hydrolysis of C3 → C3(H₂O), which binds Factor B; Factor D cleaves B → Ba + Bb; C3(H₂O)Bb is a fluid-phase C3 convertase. If C3b deposits on a non-protected surface, it recruits Factor B → Bb and forms the surface-bound C3bBb convertase, creating a positive-feedback amplification loop. This is the pathway that iptacopan blocks.

All three converge on C3 convertases that cleave C3 → C3a (anaphylatoxin, diffuses away) + C3b (opsonin, deposits). When enough C3b accumulates on a surface, a C5 convertase assembles (C4b2a3b classical/lectin, C3bBbC3b alternative) and cleaves C5 → C5a (anaphylatoxin) + C5b (nucleus of the membrane attack complex).

Downstream effectors¶

C3a, C5a — anaphylatoxins. Small (~8-11 kDa) proteolytic fragments of C3 and C5. Bind the GPCRs C3aR, C5aR1, and (for C5a) C5aR2. C5a is ~10-100× more potent than C3a as a neutrophil chemoattractant and activator; subnanomolar EC50 for chemotaxis on neutrophils.
C5b-9 — Membrane Attack Complex (MAC). C5b nucleates assembly of C6, C7, C8, and multiple C9 molecules into a transmembrane pore. On pathogens and (erroneously) host cells, MAC causes osmotic lysis. At sublytic concentrations (insufficient pore density for lysis), MAC on leukocytes and stromal cells drives calcium influx, NF-κB activation, inflammasome priming, and cytokine release. Sublytic MAC is increasingly recognized as an inflammatory driver in its own right.

Regulators — why healthy tissue does not lyse itself¶

Complement activation would destroy host cells were it not tightly regulated at every step:

Regulator	Site	Action
C1-INH	Fluid phase	Dissociates C1r/C1s and MASPs from C1q/MBL
Factor H (CFH)	Fluid phase + surface (host sialic acid / GAGs)	Cofactor for Factor I cleavage of C3b → iC3b; accelerates decay of C3bBb
Factor I	Fluid phase	Protease that cleaves C3b and C4b with appropriate cofactor
DAF (CD55)	Host cell surface	Accelerates decay of both C3 and C5 convertases
MCP (CD46)	Host cell surface	Cofactor for Factor I cleavage of C3b/C4b on host cells
CD59 (protectin)	Host cell surface	Blocks C9 polymerization → prevents MAC pore formation
C4BP	Fluid phase	Regulates classical C4b2a convertase

Genetic loss of CD55 + CD59 on erythrocytes causes paroxysmal nocturnal hemoglobinuria (PNH) — the disease eculizumab was developed for. Factor H deficiency causes atypical hemolytic uremic syndrome (aHUS) and is strongly associated with age-related macular degeneration (AMD). These "complement is already out of control" diseases are the proving grounds for complement-targeted drugs; gout is a "local over-activation, normal regulation" problem, which has different drug requirements.

Kinetics and half-lives — relevant for measurement and drug design¶

C5a is generated within minutes of a trigger surface being exposed. In serum, the C-terminal arginine is rapidly clipped by carboxypeptidase N to form C5a-desArg, which has ~10× reduced C5aR1 potency but retains partial agonism and a longer half-life. For assay purposes, commercial ELISAs typically detect both forms; "C5a" in clinical biomarker literature often means C5a + C5a-desArg. In tissue (lower CPN activity), full-length C5a persists longer. This distinction matters for serum biomarker interpretation: serum C5a underestimates tissue C5a activity.
C3a is also clipped by CPN to C3a-desArg (ASP, acylation-stimulating protein), which loses anaphylatoxin activity but retains metabolic signaling via C5L2/C5aR2. This is one reason C5aR2 biology is confusing — it binds both C5a and C3a-desArg.
C5b-9 (MAC) is slower to assemble (~minutes) but persists on membranes for hours once inserted. Soluble sC5b-9 (shed from membranes) is a stable plasma biomarker of MAC activation.

(Evidence level: In Vitro — standard complement biochemistry, well-established since the 1970s-80s.)

2. MSU Crystal → Complement Activation¶

Monosodium urate crystals are exceptional among danger signals: they activate complement directly and potently, without requiring PAMPs, antibodies, or adjuvants. This is the foundational observation on which CP0 rests.

2.1 The 1982 seed paper¶

According to PubMed, Russell, Mansen, Kolb, and Kolb (Clin Immunol Immunopathol 1982;24(2):239-50, PMID 6749358) demonstrated that MSU crystals directly activate human C5 by assembling a C5 convertase on the crystal surface. Using purified human complement components, they showed that MSU crystals:

Bound C3b and sustained alternative-pathway C5 convertase assembly (C3bBbC3b) on the crystal surface
Generated the chemotactic fragment (later named C5a) in a C5-dependent manner
Did not require antibody for activation, though classical-pathway engagement occurred when antibody was present

This was the first demonstration that a sterile crystalline danger signal could engage complement convertases on its own surface. The authors connected this to the known chemotactic / neutrophil-attracting activity of synovial fluid from acute gouty joints.

2.2 Classical pathway — IgM and CRP drive most of it¶

According to PubMed, the 2022 Wessig et al. paper (Sci Rep 2022;12(1):4483, PMID 35296708) dissected the molecular recognition events. Key findings:

Every healthy human (including unborn children) has natural IgM that binds MSU crystals. This is innate "natural antibody" — not an immune response to crystals, but constitutive polyreactive IgM from B1 cells.
CRP (C-reactive protein) binds MSU crystals and fixes active C1 complex more efficiently than IgM does.
In serum depleted of both IgM and CRP, MSU complement activation is negligible. IgM and CRP are both required to efficiently drive classical-pathway C1 activation on MSU surfaces.
CRP is more efficient than IgM at generating C5a (the most pro-inflammatory anaphylatoxin), suggesting non-redundant functions — CRP binding may orient C1 to favor downstream C5 convertase assembly.
CRP does not bind the related CPPD (calcium pyrophosphate dihydrate) crystals of pseudogout, but IgM does. This differential recognition helps explain why pseudogout and gout have subtly different complement signatures (Doherty 1988, below).

Mechanistic implication for gout: In the acute flare, the patient's baseline CRP (elevated in hyperuricemia, metabolic syndrome, and aging) plus constitutive IgM binds crystals → C1q → C4b2a classical convertase → C3b deposition → alternative-pathway amplification (C3bBb) → C5 convertase → C5a. The classical pathway initiates; the alternative pathway amplifies.

(Evidence level: In Vitro — purified serum + complement-depleted sera; IgM/CRP reconstitution experiments.)

2.3 Alternative pathway — surface amplification¶

MSU crystal surfaces also permit direct alternative-pathway engagement independent of IgM/CRP. Spontaneous fluid-phase C3 tick-over continuously deposits trace C3b; on MSU crystals, C3b is not efficiently inactivated by Factor H/I because MSU lacks the host-surface sialic acid and GAG patterns that recruit Factor H. The result is a positive-feedback amplification loop: more C3bBb convertase → more C3b → more convertase. This is the same logic that makes the alternative pathway dangerous on any non-host surface (bacteria, biomaterials, artificial membranes).

2.4 Doherty 1988 — in vivo evidence from patient synovial fluid¶

According to PubMed, Doherty et al. (Ann Rheum Dis 1988;47(3):190-7, PMID 2833185) measured C3 degradation products (C3dg/d, indicative of local C3 activation) in 288 synovial fluid samples across RA, OA, chronic pyrophosphate arthropathy, and acute pseudogout. Key finding for this page: every acute pseudogout sample had strikingly elevated synovial fluid C3dg/d (mean 61 units/mL, range 16-126), with local activation confirmed by plasma-to-synovial-fluid discordance. The acute pseudogout signal was similar in magnitude to active RA. Chronic pyrophosphate arthropathy (non-flaring) had much lower C3dg/d. Although the cohort was CPPD (pseudogout), not MSU (classical gout), the immunologic principle — crystal deposition drives active local C3 consumption in the joint — extends to MSU (which Russell 1982 had already established in vitro). Acute gout synovial fluid analyses across later decades consistently show elevated C3a, C5a, and sC5b-9.

(Evidence level: In Vitro / Clinical — human synovial fluid biomarker study.)

2.5 C5a generation timeline in murine MSU peritonitis¶

According to PubMed, Cumpelik et al. (Ann Rheum Dis 2016;75(6):1236-45, PMID 26245757) used a murine MSU peritonitis model (C57BL/6 vs. C5aR⁻/⁻) to track the kinetics:

MSU injection → C5a detectable in peritoneal lavage within 30-60 minutes
C5a precedes and is required for NLRP3-dependent IL-1β release
C5aR⁻/⁻ mice have markedly reduced IL-1β and neutrophil influx
Neutrophil-derived phosphatidylserine-positive microvesicles (PMN-Ecto) accumulate over hours and terminate C5a-mediated priming — an endogenous resolution brake via MerTK engagement

The timeline (minutes) matches the clinical tempo of a gout flare better than LPS/TLR4 priming (which requires hours of NF-κB transcription).

2.6 Relative contribution — which pathway dominates?¶

Per Wessig 2022 and Russell 1982, the classical pathway (IgM/CRP → C1 → C4b2a) is the dominant initiator; the alternative pathway amplifies rather than initiates. However, in individuals with high baseline CRP (metabolic syndrome, obesity, CKD — the gout-comorbid phenotype), classical-pathway initiation is more vigorous. In individuals with factor-H variants (rare), alternative-pathway amplification could be exaggerated. No published gout-specific polymorphism data resolve this; it is a biomarker-stratification research opportunity.

3. C5a, C3a, and MAC — Functional Roles in Gout¶

The anaphylatoxins and MAC are not interchangeable. C5a does most of the work in gout; C3a is a supporting actor; MAC is a bystander amplifier.

3.1 C5a — the dominant priming signal¶

According to PubMed, An et al. (Eur J Immunol 2014;44(12):3669-79, PMID 25229885) — the direct mechanistic study of C5a + MSU in human monocytes. This paper complements Khameneh 2017 (murine) and should be cited alongside it as the human-cell counterpart. Key findings in human whole blood and primary monocytes:

MSU-induced pro-inflammatory cytokines/chemokines in human whole blood are predominantly regulated by C5a via C5aR1
C5a alone induces pro-IL-1β and IL-1β in human primary monocytes
C5a + MSU is synergistic for IL-1β, not merely additive
C5a priming is caspase-1-dependent, K⁺-efflux-dependent, Ca²⁺-mobilization-dependent, and cathepsin B-dependent
Authors propose C5a as a therapeutic target in combination with IL-1β antagonists for gout

According to PubMed, Khameneh et al. (Front Pharmacol 2017;8:10, PMID 28167912) — murine MSU peritonitis:

C5a, not C3a, potentiates IL-1β/IL-1α release from LPS-primed, MSU-exposed peritoneal macrophages and human monocytic cells
MSU-induced C5a mediates murine neutrophil recruitment and joint-local IL-1β production
C5aR antagonism ameliorates MSU peritonitis — pharmacologic validation
Mechanism: C5a increases NLRP3 inflammasome activation via ROS production, not via transcriptional upregulation of inflammasome components. This is the non-transcriptional priming axis — the defining feature of CP0 distinct from CP1a (NF-κB transcriptional priming).

Putting these two papers together — the CP0 story:

MSU crystals directly activate complement on their surface (Russell 1982, Wessig 2022)
C5a is generated within minutes, before any NF-κB transcriptional program can ramp up (Cumpelik 2016)
C5a binds C5aR1 on tissue-resident macrophages and infiltrating neutrophils (An 2014, Khameneh 2017)
C5aR1 signaling drives NADPH-oxidase-dependent ROS burst → post-translational NLRP3 activation (Khameneh 2017)
Primed NLRP3 now responds to the crystal itself (K⁺ efflux, lysosomal rupture, mtROS — CP2) to assemble the inflammasome and release IL-1β (An 2014; the full cascade)

The critical reframe: CP0 priming is non-transcriptional and fast. LPS priming (CP1a) requires ~3-6 h of NF-κB-driven NLRP3 and pro-IL-1β transcription. C5a priming happens in minutes via ROS. Gout is fast; LPS would be too slow to explain flare kinetics.

3.2 C3a — the supporting actor¶

C3a binds C3aR (also a GPCR, Gi-coupled, on mast cells, basophils, macrophages, and some neurons). In the Khameneh 2017 experiments, C3a did not potentiate IL-1β release from MSU-exposed cells — only C5a did. This is consistent with the general rule that C5a is the dominant anaphylatoxin in myeloid activation; C3a's roles are more prominent in:

Mast cell degranulation — C3a is a more potent mast cell activator than C5a in some assays; mast cells are present in synovium and contribute to early flare histamine/tryptase release
Basophil activation — systemic
Regulatory T cell biology — C3a/C3aR signaling influences Treg function in non-gout contexts
Metabolic signaling via C3a-desArg / ASP on C5L2

For gout specifically, C3a is a probable but weak amplifier; C3aR-specific antagonism has not been clinically developed.

3.3 C5b-9 (Membrane Attack Complex) — sublytic amplifier¶

Sublytic MAC deposition on leukocytes and synoviocytes drives:

Calcium influx through the pore
NF-κB activation (inflammatory transcriptional program)
NLRP3 priming (some literature implicates sublytic MAC as a Signal 1 in its own right)
Cytokine release (IL-1β, IL-6, IL-8)
On synoviocytes: MMP release (tissue destruction in chronic gout / tophaceous joints)

The MAC contribution in gout has been under-studied. Acute gouty synovial fluid has measurable sC5b-9 (shed MAC), but quantitative comparison to C5a as the dominant effector has not been done rigorously in human gout. Mechanistic extrapolation: blocking C5 (eculizumab, ravulizumab, zilucoplan) simultaneously eliminates C5a and MAC, whereas blocking C5aR1 (avacopan) only eliminates the receptor-mediated C5a arm and leaves MAC intact. The two strategies may have meaningfully different gout outcomes.

3.4 Quantitative comparison during a flare¶

Hard quantitative data for human gout synovial fluid across C3a / C5a / MAC are sparse. Typical ranges reported across studies:

Effector	Synovial fluid (acute gout)	Plasma (acute gout)	Method	Clinical availability
C5a (+ desArg)	5-50 ng/mL	5-30 ng/mL	ELISA (cold/icy sample critical)	Send-out labs (ARUP, Mayo)
C3a (+ desArg)	100-1000 ng/mL	50-500 ng/mL	ELISA	Send-out labs
sC5b-9 (MAC)	0.5-5 μg/mL	0.1-1 μg/mL	ELISA	Send-out labs
C3 (total)	Low (consumed)	Normal-low	Turbidimetry	Standard
C4 (total)	Low (consumed)	Normal-low	Turbidimetry	Standard
CH50	Low (consumption)	Low-normal	Functional	Standard

Ranges are approximate; cite specific studies for exact values. C5a is 10-100× less abundant by mass than C3a but vastly more potent per molecule, consistent with its dominant functional role.

4. Receptor Biology¶

4.1 C5aR1 (CD88) — the main effector receptor¶

Gene: C5AR1 (HGNC:1338, chromosome 19q13.3-q13.4). Protein: 350 aa, 7-transmembrane class A GPCR (rhodopsin family, anaphylatoxin receptor subfamily IPR002234). ChEMBL target: CHEMBL2373 (SINGLE PROTEIN, Homo sapiens, UniProt P21730).

Expression: Neutrophils (high), monocytes/macrophages, mast cells, basophils, eosinophils, dendritic cells, hepatocytes, lung and renal epithelium, astrocytes/microglia, vascular endothelium (low but inducible), fibroblast-like synoviocytes, osteoclast precursors. Essentially every innate immune cell and many stromal cells.

G-protein coupling: Primarily Gαi (inhibits cAMP, activates PI3K/AKT, ERK½) and Gαq/11 (activates PLCβ → IP3 + DAG → calcium mobilization + PKC). The calcium flux and ERK activation are the dominant signals; cAMP inhibition is less critical.

Downstream of C5aR1 engagement (the full signaling tree):

NADPH oxidase assembly (NOX2) → ROS burst — this is the defining priming signal for NLRP3 in Khameneh 2017
Calcium mobilization via PLCβ — feeds into Ca²⁺-dependent NLRP3 activation
ERK½ MAPK — amplifies inflammatory transcription
PI3K/AKT — survival and chemotactic signaling
Actin remodeling → chemotaxis (subnanomolar C5a concentration gradient is sufficient to direct neutrophil migration)
Degranulation (neutrophils release MPO, elastase, lactoferrin)
Upregulation of adhesion molecules (Mac-1/CD11b on neutrophils; P-selectin/ICAM-1 on endothelium)

β-arrestin recruitment follows agonism and drives receptor internalization and desensitization. Avacopan is biased toward blocking G-protein signaling with less effect on β-arrestin recruitment, which may contribute to its safety profile (less complete receptor shutdown preserves some normal functions).

Structural biology. According to PubMed, Liu et al. (Nat Struct Mol Biol 2018;25(6):472-481, PMID 29867214) solved crystal structures of human C5aR1 in ternary complex with PMX-53 (orthosteric peptide antagonist) and with avacopan or NDT-9513727 (non-peptide allosteric antagonists). Key findings:

PMX-53 binds the orthosteric pocket where C5a's C-terminus normally docks — direct competition
Avacopan binds an allosteric site distinct from the orthosteric pocket, stabilizing an inactive conformation
The allosteric site is on the intracellular side of the receptor, near helix 8
Structure-based drug design for orally bioavailable C5aR1 antagonists is now tractable — avacopan is the proof of concept

Known PDB structures: 5O9H, 6C1Q, 6C1R, 7Y64-7Y67, 8GO8, 8GOO, 8HK5, 8I0N, 8I0Z, 8IA2, 8JZP, 8JZZ.

Gout-relevant polymorphisms. No published C5AR1 polymorphisms are directly associated with gout susceptibility in current GWAS. Large gout GWAS (351-loci meta-analysis, UK Biobank 2025) are dominated by urate-transporter signals (ABCG2, SLC2A9, SLC22A12); complement-receptor variants would likely be smaller effects and possibly modify flare severity rather than hyperuricemia itself. This is an open research question (§6).

4.2 C5aR2 (C5L2) — the enigmatic second receptor¶

Gene: C5AR2 (HGNC:4527, chromosome 19q13.32 — adjacent to C5AR1). Protein: 337 aa, 7-transmembrane topology but with two substitutions (DRY → DLC motif) that prevent canonical G-protein coupling. ChEMBL target: [CHEMBL3713] (within the CHEMBL4523605 heterodimer record).

Binds: C5a (same affinity as C5aR1), C5a-desArg (higher affinity than C5aR1 has for desArg — C5L2 may preferentially respond to the decay product), and C3a-desArg / ASP.

Signaling: Non-G-protein-coupled; engages β-arrestin and scaffolds. Literature is split on whether C5aR2 is:

A decoy receptor that sequesters C5a and dampens C5aR1 signaling (pro-resolution)
A pro-inflammatory signaling receptor in its own right, driving distinct cytokine programs
A modulator of C5aR1 signaling via heterodimerization (both receptors physically associate on the plasma membrane)

In gout specifically, C5aR2's role has not been dissected. C5aR2⁻/⁻ mice have been studied in sepsis and kidney injury with mixed results. For CP0 therapeutic design, this is a known unknown. Avacopan is C5aR1-selective, not C5aR2; if C5aR2 is pro-inflammatory in gout, avacopan could miss a portion of the signal. If C5aR2 is a decoy, avacopan is better off leaving it alone. Zilucoplan and eculizumab (upstream C5 inhibitors) block both arms by preventing C5a generation.

4.3 C3aR — the C3a receptor¶

Gene: C3AR1. Protein: 482 aa, 7-TM class A GPCR, Gαi-coupled, with long extracellular loops. Expression: Mast cells (high), basophils, eosinophils, neutrophils, monocytes/macrophages (moderate), brain microglia and astrocytes, adipocytes.

Gout relevance: Weaker than C5aR1 per the Khameneh 2017 data (no IL-1β potentiation by C3a). Possibly relevant via mast-cell histamine/tryptase release in early flare vascular permeability.

Clinical targeting: No approved C3aR antagonist. Preclinical compounds (SB 290157) have off-target issues.

4.4 Structural implications for drug design¶

Avacopan's allosteric site on C5aR1 (Liu 2018) suggests:

Off-target profile. Avacopan is structurally unlike C5a; it does not mimic the endogenous ligand. This is favorable for selectivity but limits cross-reactivity with related anaphylatoxin receptors.
Resistance concerns. Allosteric-site mutations could in principle cause resistance; none have been reported clinically.
Drug design space. The allosteric site is druggable with non-peptide small molecules — unlike orthosteric sites on peptide-binding GPCRs, which are notoriously hard for small molecules. This is why oral C5aR1 antagonists became feasible in the 2010s when they had been stuck in peptide-only space for two decades.

Natural-product implication: Because C5aR1's orthosteric site is peptide-binding and its allosteric site is a pocket discovered by synthetic medicinal chemistry, natural-product chemical space has not been efficiently searched against this target. Most natural product screens against "complement" test for pathway inhibition (e.g., CH50 assays) rather than receptor-specific antagonism, so latent C5aR1 antagonist activity in known natural products could be under-recognized. This is one of the sharpest research opportunities on this page (§10).

5. Cell Biology of C5a in a Gout Flare¶

C5a does not act on one cell type — it orchestrates the early-flare cellular storm through coordinated effects on myeloid cells, endothelium, and stroma.

5.1 Neutrophil chemotaxis — the first wave¶

C5a is the most potent single neutrophil chemoattractant known, driving directed migration at subnanomolar concentrations. In a gout flare:

MSU crystals in the joint activate complement (minutes)
C5a diffuses into local microvasculature (diffusion-limited, ~minutes)
Endothelium responds to C5a (see §5.4) — upregulates P-selectin, ICAM-1
Circulating neutrophils tether, roll, adhere on activated endothelium
Neutrophils transmigrate into the synovium, following the C5a gradient to the crystal-rich tissue
Once in the tissue, neutrophils encounter crystal directly — phagocytose, activate their own NLRP3 (crystal engulfment → lysosomal rupture → K⁺ efflux → CP2)
Activated neutrophils release more C5a (via serine proteases acting on C5) and IL-8 — amplification loop

This is why gout flares have a neutrophil-dominant infiltrate within hours and why blocking C5aR1 (avacopan) or C5 itself (zilucoplan, eculizumab) could theoretically abort the flare at its earliest effector step.

5.2 Macrophage priming — the CP0 mechanism¶

Per An 2014 and Khameneh 2017, resident joint macrophages are already in place when crystals deposit. C5a acts on them via C5aR1 → PI3K → NOX2 activation → ROS burst → post-translational NLRP3 priming (protein-level changes: phosphorylation, oligomerization-competence, de-ubiquitination), making NLRP3 responsive to the activation signal from crystal-triggered K⁺ efflux. Without CP0 priming, MSU crystal engagement of NLRP3 is subthreshold in resting macrophages in vitro; priming is required.

5.3 Fibroblast-like synoviocytes (FLS)¶

FLS express C5aR1. In rheumatoid arthritis (where FLS biology is best-characterized) and OA, C5a exposure induces IL-6, IL-8, MMP-1, MMP-3, and VEGF. The parallel in gout is mechanistically expected but not specifically characterized in published MSU + FLS assays. FLS are likely contributors to the IL-6 and VEGF signals that TNFSF14 paper (Ea 2024, PMID 38373842; see tnfsf14-gout-target.md) identified as top gout-flare biomarkers. Avacopan would be expected to reduce this synoviocyte-derived cytokine arm.

5.4 Endothelial activation¶

C5aR1 is weakly expressed on resting endothelium but is induced by inflammatory cytokines. More important: C5a acts on endothelium indirectly via mast-cell-derived histamine and platelet-derived mediators, and directly at higher concentrations. Effects:

Upregulation of P-selectin (from Weibel-Palade body stores — rapid, minutes)
Upregulation of ICAM-1 (transcriptional, hours)
Increased vascular permeability — tissue edema
Platelet activation (C5aR1 on platelets in some contexts)

These effects together create the neutrophil-recruitment phenotype characteristic of the early flare.

5.5 Mast cells and basophils¶

C5a activates mast cells via C5aR1 → histamine, tryptase, leukotriene release → immediate-type tissue responses. Mast cells are present in synovium at low density but may contribute to the earliest vascular-permeability phase of the flare. C3a is a more potent mast-cell trigger than C5a in some studies.

5.6 Osteoclasts — long-term damage¶

Osteoclast precursors express C5aR1. Chronic complement activation in tophaceous gout may contribute to bone erosion. This is mechanistically plausible but under-studied; no gout-specific osteoclast / C5a data have been published. Implication: chronic avacopan (or similar) might have a bone-sparing side benefit in tophaceous disease.

6. Genetics and Clinical Heterogeneity¶

This section is deliberately thin — the literature is thin. That is itself a finding.

6.1 C5 polymorphisms¶

No published GWAS signal connects C5 variants to gout risk or flare severity. C5 variants (notably rs17611) are associated with rheumatoid arthritis severity and some autoimmune phenotypes. Given the complement-centric mechanism of gout, this is a surprising gap — possibly explained by (1) gout GWAS being dominated by urate transporter signals with much larger effect sizes, (2) sample sizes insufficient for complement-pathway sub-signals, and (3) flare-severity endpoints being less well-powered than hyperuricemia endpoints.

6.2 C5AR1 / C5AR2 / C3AR1 polymorphisms¶

No published gout-association data for C5AR1, C5AR2, or C3AR1 variants. For C5AR1 specifically, variants are characterized in ANCA vasculitis cohorts (ADVOCATE biomarker substudies) and inflammatory bowel disease, but the work has not extended to gout. Open question: does a C5AR1 variant patient respond differently to avacopan in ANCA vasculitis? If yes, the same logic would transfer to a future gout trial.

6.3 Factor H (CFH) variants¶

CFH Y402H (rs1061170, p.Tyr402His) is the canonical common variant dysregulating alternative-pathway complement amplification. The risk C-allele has frequency ~36–39% in Europeans, ~35–37% in Africans (parity with European, not lower as some reviews state), ~30% in South Asians, ~5–6% in East Asians, and ~18–32% in Latino/Admixed populations (gnomAD v4 / ALFA / 1000 Genomes 2026 access; corrects the earlier "~30–50% European, ~7% East Asian" framing which conflated AMD-case ascertainment with population frequencies). The variant reduces CFH's ability to bind C-reactive protein and host glycosaminoglycans, weakening inactivation of surface-deposited C3b — predicted to amplify alternative-pathway C5a generation on MSU crystals, producing more vigorous flares.

No published gout-association data connect CFH variants to gout risk, severity, or flare frequency. This is the canonical complement-genetics gap, consistent with §6.1 — published gout GWAS (Tin 2019, Major 2018, Kawamura 2019 UK Biobank n=150,542) do not detect complement-pathway sub-signals at genome-wide significance, plausibly because (1) urate-transporter signals dominate gout GWAS effect-size distributions, (2) flare-severity endpoints are less well-powered than hyperuricemia endpoints, and (3) the complement-priming axis acts conditionally on MSU crystallization rather than as an unconditional gout-risk modifier.

Supportive intermediate-phenotype evidence:

Hecker 2023 (Front Immunol, PMID 37940657, n=153 healthy + 84 dry AMD + 143 neovascular AMD): CFH 402HH homozygotes had elevated baseline CRP (38% of healthy 402HH in the 3–10 mg/L range vs 10% in 402YH carriers, p=0.037) and depressed CD4+ T-cell proportions with aging. CRP elevation is upstream of classical complement priming on MSU crystals (per §5).
Volcik 2008 ARIC (PMID 18292760, n=15,792): CFH 402H × hypertension interaction → HRR 1.47 (95% CI 1.05–2.05) for ischemic stroke in white 402HH; HRR 1.19–1.28 for CHD in hypertensive 402H carriers. Effect absent in African Americans, suggesting population-specific effect-direction differences. Consistent with the priming-gradient framework.

The dietary-CP0 stratification prediction (added 2026-05-19, untested): the comp-018 / comp-020 dietary CP0 candidates (rosmarinic acid C3 convertase inhibition, luteolin CH50/AP50, Houttuynia cordata polysaccharide multi-target) are mechanistically positioned to bypass the CFH-mediated complement-regulation axis (they prevent C3 convertase assembly upstream of where Y402H matters), suggesting CFH Y402H carriers should benefit MORE from dietary CP0 blockade than wild-type carriers — the same stratification logic as ABCG2 Q141K × butyrate per abcg2-modulators.md §6.

⚠️ Counter-evidence from CFH × diet × AMD analog (added 2026-05-19): three independent published analyses point the opposite direction.

Klein 2008 / Awh 2013 / Vavvas 2018 (PMID 18423869 / 23972322 / 29311295; AREDS n=989/802 with bootstrap validation n=412): CFH high-risk + no ARMS2 risk genotype group (GTG2) had paradoxically increased progression to neovascular AMD on AREDS formulation (zinc 80 mg + antioxidants) vs placebo (HR 2.9, p=0.018). CFH low-risk + ARMS2 high-risk (GTG3) benefited (HR 0.50, p=0.008).
Merle 2015 NAT2 (PLoS ONE PMID 26132079, n=250): CFH × DHA-supplementation interaction p=0.01. DHA was protective only in CFH 402YY (non-risk homozygous; CNV 38.2% placebo vs 16.7% DHA, p=0.008); CFH 402CC homozygotes had numerically MORE CNV on DHA (23.1% placebo vs 39.5% DHA).
Chew 2014 AREDS Report #38 (PMID 24974817, n=1,237): null result — no significant CFH × treatment interaction. The literature is heterogeneous.

The mechanism interpretation that may rescue the OE prediction: AREDS-zinc and DHA work through complement regulation that requires functional CFH (Vavvas 2018 attributes the GTG2 paradox to zinc-induced complement inactivation requiring CFH-CRP bridging, which CFH 402H performs poorly). Rosmarinic acid / luteolin / Houttuynia work by direct convertase inhibition or polysaccharide-mediated CP/LBP blockade — neither requires functional CFH. The dissociation is mechanistically plausible but empirically untested.

Biobank feasibility: the cross-tabulation (UK Biobank CFH rs1061170 × dietary polyphenol intake × incident gout M10.x) is technically straightforward — rs1061170 is on the standard Axiom array; gout outcomes + Oxford WebQ dietary recall + Phenol-Explorer-derived polyphenol intake are all standard fields with published precedent (Yokose 2024 Rheumatology for gout × diet UKB methodology; Bondonno 2025 Nature Food for flavonoid-diversity × outcome UKB methodology). OE does not currently hold a UK Biobank application; the practical paths are (a) collaboration with existing gout-GWAS groups (Merriman/Otago, Major-Wrigley/Auckland, Choi/MGH) who already have UKB access and gout-extraction pipelines, ~3-month timeline, $0 OE cost; (b) AoU Researcher Workbench credentialing for a parallel direction-check in a smaller cohort with better African-American representation, ~2-4 weeks; © primary UKB application, ~6-12 months + £3-9K. Full mining report: logs/cfh-y402h-dietary-cp0-biobank-mining-2026-05-19.md.

6.4 Gout phenotype heterogeneity — does complement differ by subtype?¶

Clinical phenotypes of gout that might have distinct complement profiles:

Phenotype	Hypothesized complement difference	Testable how
Acute intermittent vs. chronic tophaceous	Tophaceous has chronic low-grade complement activation; acute has cyclic spikes	Serum C3/C4/sC5b-9 longitudinal
CKD-associated vs. idiopathic	CKD patients have higher baseline CRP → more classical-pathway priming on crystals	Pre-flare CRP; in-flare C5a generation
Metabolic syndrome vs. lean	MetSyn patients have higher baseline complement activation; LPS translocation also contributes	Fecal calprotectin + serum LBP + C5a
Post-menopausal women vs. men	Sex hormones affect complement (estrogen slightly suppresses); women have later and different gout	Sex-stratified complement biomarker study
Pegloticase responders vs. non-responders (ADA-driven failure)	Non-responders develop immune complexes → additional complement activation → worse flares	C3a / sC5b-9 around infusions

None of these have been rigorously studied in published gout cohorts. All are testable with existing biobanked sera and flare-phase sampling — concrete experiment opportunities.

7. Therapeutic Landscape at CP0 (Deepened)¶

This is the actionable section: what exists, how it works, cost and access, and what would plausibly repurpose for gout.

7.1 Avacopan (Tavneos, Amgen formerly ChemoCentryx) — the obvious gout repurposing candidate¶

Repurposing surface origin: Avacopan is one of three concrete examples surfaced by the Open Enzyme discovery engine's chokepoint-to-FDA-drug mapping methodology — FDA-approved drugs that hit a gout chokepoint but were never clinically tested for gout. The other two are zileuton (CP6a 5-LOX, FDA-approved for asthma) and disulfiram (CP6b GSDMD, FDA-approved for alcohol use disorder). See open-enzyme-vision.md §2.2 for the full repurposing surface framing. (source: etc/open-enzyme-vision.md)

Mechanism: Oral small-molecule C5aR1 allosteric antagonist (Liu 2018 structure confirms allosteric binding). Selective for C5aR1 over C5aR2. ChEMBL CHEMBL3989871. ATC L04AJ05.

Chemistry: MW 581.7, cLogP 8.05 (very lipophilic), aromatic 3, 2 Ro5 violations (the MW is the issue; cLogP is the other). SMILES: Cc1ccc(NC(=O)[C@H]2CCCN(C(=O)c3c(C)cccc3F)[C@H]2c2ccc(NC3CCCC3)cc2)cc1C(F)(F)F. Lipophilicity drives the oral bioavailability despite the MW being over 500.

Clinical: According to PubMed, the ADVOCATE trial (Jayne et al. NEJM 2021;384(7):599-609, PMID 33596356) — Phase 3 RCT in ANCA-associated vasculitis, N=331 randomized, avacopan 30 mg BID oral vs. tapered prednisone, both arms + cyclophosphamide or rituximab background. Primary endpoints:

Remission at week 26: avacopan 72.3% vs. prednisone 70.1% (non-inferior; p<0.001)
Sustained remission at week 52: avacopan 65.7% vs. prednisone 54.9% (superior; p=0.007)
Serious adverse events (excluding vasculitis worsening): 37.3% vs. 39.0% (similar)

FDA approval October 2021 for ANCA-associated vasculitis (granulomatosis with polyangiitis, microscopic polyangiitis) as adjunctive therapy. EMA approval 2022.

PK: Oral bioavailability ~25-45%; Tmax 2 h; t½ ~1.7 days (steady state by day 7); highly protein-bound (>99%); metabolism is CYP3A4-dominant → strong CYP3A4 inhibitors (ketoconazole, clarithromycin, ritonavir) require dose reduction to 30 mg QD; strong CYP3A4 inducers (rifampin) should be avoided. Food increases exposure. No renal dose adjustment; hepatic impairment requires caution (liver enzyme elevations occur in ~13% of treated patients — boxed warning for hepatotoxicity monitoring).

Drug-drug interactions of note for gout patients: allopurinol, febuxostat, colchicine have no direct CYP3A4 interaction with avacopan, so co-administration should be PK-safe. Colchicine's metabolism involves CYP3A4 and P-gp but avacopan is not a strong CYP3A4 inhibitor.

Cost: Wholesale acquisition cost in the US ~$150,000-200,000/year (2023-2024 estimates for ANCA). Not affordable at population scale; a gout repurposing would be a niche use (refractory-flare, pegloticase-bridge, crystal-dissolution-window) rather than first-line.

Gout data: None published. No registered gout trial. A reasonable rheumatologist would consider off-label use in a severe refractory-flare-prone gout patient (e.g., pegloticase failures with ongoing tophi). Prescribing is specialist-only in practice.

7.2 Vilobelimab (Gohibic, InflaRx) — anti-C5a mAb, IV¶

Mechanism: IgG4κ humanized monoclonal antibody that binds C5a directly, neutralizing C5a-driven C5aR1 and C5aR2 signaling. Does not block C5 cleavage — so MAC (C5b-9) is preserved, and terminal bactericidal complement function is intact. This is a meaningful differentiation from eculizumab (which blocks C5 cleavage entirely and eliminates both C5a and MAC).

ChEMBL: CHEMBL2109636 (antibody, max phase 3 for most indications, FDA EUA for severe COVID-19 in 2023).

Clinical: According to PubMed, PANAMO Phase 3 (Vlaar et al. Lancet Respir Med 2022;10(12):1137-1146, PMID 36087611) — randomized double-blind in 368 invasively-ventilated COVID-19 patients. 28-day all-cause mortality: vilobelimab 32% vs. placebo 42% (HR 0.73, p=0.094 stratified; HR 0.67, p=0.027 unstratified). FDA EUA April 2023 for severe COVID-19 in invasively ventilated patients. PANAMO Phase 2 (PMID 33015643) and PK study (Lim et al. Intensive Care Med Exp 2023;11(1):37, PMID 37332066) — C5a levels dropped ~87% by day 8; no treatment-emergent ADAs in 93 patients sampled.

Dosing: 800 mg IV on days 1, 2, 4, 8, 15, 22 (six doses total). t½ ~2-3 days between doses; steady state not fully modeled. Not a chronic-use drug in its current form.

Gout relevance: C5a-specific neutralization would test a cleaner hypothesis than avacopan (C5aR1 antagonism misses C5aR2; vilobelimab catches both receptor signals but preserves MAC). IV dosing limits practical gout use. Conceptually interesting as a mechanistic probe.

7.3 Zilucoplan (Zilbrysq, UCB) — macrocyclic peptide C5 inhibitor, SC¶

Mechanism: Synthetic 15-amino-acid macrocyclic peptide that binds C5 at a novel site and blocks its cleavage by the C5 convertase → no C5a, no C5b, no MAC. ChEMBL CHEMBL4298207 (parent) / CHEMBL5315048 (sodium salt, approved). ATC L04AJ06.

Clinical: According to PubMed, RAISE Phase 3 (Howard et al. Lancet Neurol 2023;22(5):395-406, PMID 37059508) — N=174, zilucoplan 0.3 mg/kg SC daily vs. placebo, 12 weeks. MG-ADL change -4.39 (zilucoplan) vs. -2.30 (placebo), difference -2.09 (p=0.0004). FDA approval October 2023 for generalized myasthenia gravis (AChR-autoantibody-positive). Durable efficacy through 24 weeks (de la Borderie 2024, PMID 39314260).

PK: SC self-administered daily; binds C5 with high affinity; t½ ~9 days at steady state (long residence on C5).

Safety: Boxed warning — meningococcal infection. Vaccination with MenACWY and MenB required ≥2 weeks prior to starting; antibiotic prophylaxis if urgent initiation. Injection-site reactions 16%.

Cost: Wholesale ~$600,000/year (MG pricing).

Gout relevance: Daily SC is less patient-friendly than oral avacopan. The meningococcal risk, while manageable, is a hard barrier for chronic use in a non-life-threatening condition like gout. Unlikely gout repurposing unless a specific acute / bridge-dosing use case emerges.

7.4 Eculizumab (Soliris, Alexion/AstraZeneca) — anti-C5 mAb, IV¶

Mechanism: Humanized IgG2/4κ anti-C5 monoclonal antibody. Binds C5 at a site that prevents C5 convertase cleavage → no C5a, no MAC. ChEMBL CHEMBL1201828. ATC L04AJ01.

Approvals: FDA 2007 for PNH (paroxysmal nocturnal hemoglobinuria); 2011 for aHUS (atypical hemolytic uremic syndrome); 2017 for generalized MG; 2019 for NMOSD (neuromyelitis optica spectrum disorder).

Dosing: 900 mg IV weekly × 4, then 1200 mg IV every 2 weeks. t½ ~11 days.

Safety: Boxed warning — meningococcal infection (risk ~1000× general population). Vaccination required. Other encapsulated-organism infections. Sepsis screening protocols.

Cost: ~$500,000-750,000/year. Biosimilars (Bekemv, Epysqli) now available at discounted prices.

Gout relevance: The original systemic C5 inhibitor. IV infusion + cost + meningococcal risk make it impractical for gout beyond compassionate use in pegloticase-induced immune-complex vasculitis.

7.5 Ravulizumab (Ultomiris, Alexion/AstraZeneca) — long-acting eculizumab¶

Mechanism: Engineered version of eculizumab with Fc mutations (YTE-like) giving ~4× longer half-life via FcRn recycling. Same epitope on C5. ChEMBL CHEMBL3989986. ATC L04AJ02.

Dosing: IV every 8 weeks (vs. every 2 weeks for eculizumab).

Approvals: PNH (2018), aHUS (2019), gMG (2022), NMOSD (2024).

Gout relevance: Same as eculizumab — IV + meningococcal risk make it impractical for non-life-threatening use.

7.6 Iptacopan (Fabhalta, Novartis) — oral Factor B inhibitor, alternative pathway¶

Mechanism: Oral small-molecule inhibitor of Factor B, blocking alternative-pathway amplification. Leaves classical/lectin pathways intact. ChEMBL CHEMBL4594448. ATC L04AJ08.

Chemistry: MW 422, cLogP 4.93, Ro5 compliant (0 violations, QED 0.56). More drug-like than avacopan.

Dosing: 200 mg oral BID.

Approvals: FDA December 2023 for PNH; 2024 for IgA nephropathy; 2024/2025 for C3 glomerulopathy (per ATC labeling).

Gout relevance: The alternative pathway amplifies MSU-triggered C5a generation but is not the sole pathway (classical-pathway IgM/CRP is the initiator per Wessig 2022). Iptacopan would reduce but not eliminate CP0 activation. Interesting as a mechanistic tool to quantify alternative-pathway contribution. Meningococcal warning applies.

7.7 Research compounds (not clinically approved)¶

Compound	Mechanism	Status	Notes
PMX-53	Cyclic hexapeptide C5aR1 orthosteric antagonist	Preclinical	Most widely-used research tool; IC50 ~20 nM on human PMN C5aR1. Not orally stable.
PMX-205	PMX-53 derivative with improved oral bioavailability	Preclinical	Rat-tested; no human data
JPE-1375	Peptide C5aR1 antagonist	Preclinical
NDT-9513727	Small-molecule C5aR1 allosteric antagonist	Discontinued	Co-crystallized with C5aR1 (Liu 2018); structure-guide for avacopan follow-ons
W-54011	Small-molecule C5aR1 antagonist	Preclinical
CCX-168 (pre-avacopan)	ChemoCentryx's avacopan precursor	Became avacopan

7.8 Comparative summary¶

Drug	Target	Route	t½	Gout plausibility	Block MAC?
Avacopan	C5aR1	Oral 30mg BID	1.7 d	High — oral, mechanism-aligned, precedent in ANCA	No (leaves MAC)
Vilobelimab	C5a	IV	2-3 d	Medium — IV limits chronic use, but mechanistic probe	No (leaves MAC)
Zilucoplan	C5	SC daily	9 d (steady)	Low — SC daily + meningococcal	Yes
Eculizumab	C5	IV q2w	11 d	Low — IV + cost + meningococcal	Yes
Ravulizumab	C5	IV q8w	50+ d	Low — IV + cost + meningococcal	Yes
Iptacopan	Factor B	Oral BID	25 h	Medium — oral, but only blocks alternative pathway	Partial
PMX-53	C5aR1	Research	Short	N/A — preclinical only	No

Avacopan is the clear gout repurposing lead based on route (oral), selectivity (C5aR1-only leaves MAC intact and preserves antibacterial terminal complement), and precedent (FDA-approved).

8. Combination Biology — C5a vs. LPS vs. TNFSF14 Priming¶

A central unresolved question: is gout priming purely C5a-dominant, or does LPS (from gut translocation / SIBO / metabolic endotoxemia) and TNFSF14 (amplifier — see tnfsf14-gout-target.md) contribute additively?

8.1 Why the question matters¶

If CP0 (C5a) is sufficient → avacopan alone would substantially abort flares. If CP0 + CP1a (LPS/TNFSF14) are additive → partial efficacy at best; combination CP0+CP1a blockade needed. If priming signals are fully redundant → blocking CP0 yields minimal clinical benefit (LPS picks up the slack).

8.2 What the literature shows¶

An 2014 (PMID 25229885) — C5a + MSU is synergistic in human monocytes, with C5a priming dominant over background LPS in whole blood
Khameneh 2017 (PMID 28167912) — C5aR⁻/⁻ mice have markedly reduced IL-1β in MSU peritonitis, suggesting C5a is not redundant with other priming signals; LPS-primed macrophages still need C5a for maximal MSU-induced IL-1β
Cumpelik 2016 (PMID 26245757) — Neutrophil-derived PMN-Ecto suppresses specifically the C5a arm; their resolution effect depends on C5aR engagement, implying C5a is the relevant physiologic priming signal

Taken together: C5a is necessary and largely sufficient for full flare priming in experimental systems. LPS priming is more of a laboratory artifact (used because it is convenient in vitro) than a gout-physiologic signal.

8.3 Real-world caveats¶

Metabolic syndrome + SIBO patients likely have elevated systemic LPS via gut permeability → LBP/sCD14 elevation → systemic low-grade inflammation. In these patients, LPS priming could additively contribute to NLRP3 priming alongside C5a. Mechanistic extrapolation: avacopan alone might be less effective in this patient subgroup; combination with gut-barrier repair (butyrate, berberine-driven microbiome shift, glutamine) may be needed.
TNFSF14 amplifier loop (Ea 2024) likely adds to NF-κB-driven priming in the subset of patients with high TNFSF14 at flare onset. TNFSF14 operates via NF-κB, so it is distinct from the C5a → ROS axis and could be additive.

8.4 Species differences¶

Dapansutrile's 3-order-of-magnitude IC50 gap between mouse and human cells (see nlrp3-exploit-map.md species-gap caveat) is a warning against direct translation of rodent C5a mechanisms. Specific C5a-gout species differences to note:

Murine C5aR1 is ~70% identical to human; some antagonists are species-selective
Murine complement activates more efficiently on some surfaces than human
PMX-53 has mouse cross-reactivity; avacopan is less active on murine C5aR1 (human-selective)

Implication: the Khameneh 2017 murine validation of C5aR antagonism is mechanistically supportive but not a clinical prediction. An avacopan gout trial is necessary.

9. Open Enzyme Platform Gap at CP0¶

9.1 The honest gap¶

The Open Enzyme stack — engineered koji/yeast producing uricase, kojic acid, taurine, carnosine, quercetin, ursolic acid, lactoferrin, and candidate NLRP3 modulators — has no direct CP0 coverage. No compound in the stack is a characterized C5a/C5aR1/C3aR inhibitor. The natural-product chemical space at C5aR1 was scanned computationally on 2026-04-27 (validation-experiments §1.21) — zero wet-lab-validated natural-product antagonists; the door on fermentable CP0 coverage is closed pending one of the re-open conditions in §1.21. This is not a hedge; it is a structural feature of the platform:

C5aR1's allosteric site is a synthetic-chemistry creation (avacopan, NDT-9513727). Natural products have not been efficiently screened there.
C5aR1's orthosteric site is a peptide pocket; the only effective antagonists are synthetic constrained peptides (PMX-53).
The approved C5-binding drugs (eculizumab, ravulizumab, zilucoplan) are a mAb, a mAb, and a macrocyclic peptide — none are microbial-fermentation products of the size / structure that GRAS yeast or koji would produce at scale.

9.2 Primary upstream effect — uricase's indirect CP0 impact¶

The engineered-koji uricase strategy is upstream of CP0, not at CP0. The logic:

Uricase degrades uric acid → urate below MSU saturation threshold → no crystal formation → no complement activation surface → no C5a generation
Over months to years, existing tophi dissolve → smaller crystal load → fewer priming events per flare
Complete uricase kill would eliminate CP0 entirely (no crystals = no complement trigger)
Partial uricase kill leaves residual crystal formation, which still triggers CP0 — the full downstream cascade activates

9.3 Secondary effects¶

Gut mucosal complement activation from luminal MSU in hyperuricemia has not been well-characterized. Engineered koji uricase would reduce any luminal-crystal-driven mucosal complement activation.
Serum uric acid as a soluble danger signal (separate from crystalline): high serum UA alone is not a strong complement activator; crystal surface is the critical CP0 trigger. So the benefit of uricase on CP0 is mediated almost entirely through preventing crystal formation, not through scavenging soluble urate.

9.4 Timing mismatch¶

Complement activation at the joint happens in minutes of crystal contact; uricase works on a months-to-years timeline for crystal dissolution. Engineered koji does not attack CP0 acutely. An active flare is not aborted by activating the uricase (even if it were instantaneously efficacious in the gut, the joint crystals are already triggering C5a).

9.5 Open Enzyme strategic position¶

The Open Enzyme platform should be honest about this: it is a "downstream damper" and a "crystal eliminator", not an acute flare preventer at priming. Avacopan (a synthetic pharma adjunct) covers CP0; Open Enzyme covers the crystal surface upstream and the CP1b/CP2/CP5 downstream chokepoints. They are complementary, not redundant.

For a refractory patient with active flares, the logical stack is:

Uricase (engineered koji or pegloticase / SEL-212 / PRX-115) — eliminate the crystal trigger upstream
Avacopan (off-label bridge) — cover CP0 priming during the crystal-dissolution window (months to years when tophus fragments could precipitate flares)
Open Enzyme downstream stack (CP1a NF-κB blockers, CP2 K⁺ blockers, CP5 IL-1β SPM resolvers) — cover the downstream chokepoints to reduce residual flare intensity
Taper avacopan once crystal burden is minimal and flare frequency is below a threshold

This is the honest combination: pharma at CP0 + platform at CP1-6 + pharma/platform at upstream crystal elimination.

9.6 Research opportunity — screen natural products against C5aR1¶

Because C5aR1 has not been well-characterized in natural-product chemical space (§4.4), an unbiased screen of known natural products against human C5aR1 (using β-arrestin recruitment or calcium-flux functional readout, or radioligand displacement from neutrophil C5aR1) could surface latent antagonists. Candidates worth screening first based on reported complement-pathway activity:

Quercetin, luteolin, apigenin (flavonoids with broad anti-inflammatory activity; some reported complement inhibition in CH50 assays but no C5aR1-specific data)
EGCG (polyphenol; modulates NF-κB, already in stack; any C5aR1 affinity unknown)
Ursolic acid (triterpenoid; broad anti-inflammatory; unknown at C5aR1)
Curcumin (known NF-κB inhibitor; C5aR1 unknown)
Resveratrol, pterostilbene (SIRT1 activators; C5aR1 unknown)
Berberine (isoquinoline alkaloid; known microbiome modulator; C5aR1 unknown)
Kojic acid (A. oryzae native; weakest prior expectation but relevant to platform)

Expected outcome: most will be negative or weak (low-μM at best). If any shows sub-μM C5aR1 antagonism, it is a significant finding and worth medicinal-chemistry follow-up on the koji-expressible scaffold. This is a concrete experiment — one 384-well plate, ~20 compounds, ~1 day of assay time.

9.7 Combined CP0 strategy (testable hypothesis) — dietary rosmarinic acid + engineered DAF SCR1-4 (added 2026-05-15)¶

The OE corpus has two CP0 threads that have advanced in parallel without being named as a combined strategy:

Dietary upstream-complement thread. comp-018 + comp-020 identified rosmarinic acid as a candidate C3 convertase inhibitor via covalent C3b modification — Englberger 1988 (PMID 3198307) primary mechanism, ~30 years of indexed primary literature, IC50 reported around 34 μM but with a 44× spread across assay formats (comp-020 verification re-run). Mechanism distinctive at the C3b deposition step rather than direct C5 convertase inhibition.

Fourth Tier 1 candidate — Houttuynia cordata polysaccharide (added 2026-05-19, Cluster K walkthrough). comp-018 Phase 2 identified Houttuynia cordata (魚腥草 / どくだみ / Vietnamese diếp cá — widely-consumed Southeast Asian dietary herb) polysaccharides as Tier 1d alongside rosmarinic acid, luteolin, and Helicteres lignans. CH50 79–318 µg/mL across crude + purified fractions; multi-target at C2 + C4 + C5 (Chen Daofeng / Fudan group in vivo precedents). The mechanism is distinct from rosmarinic acid's covalent-C3b-modification — Houttuynia polysaccharides operate at multiple cascade entry points (classical + lectin + alternative) via polysaccharide receptor engagement. CP1 extension — Houttuynia uniquely doubles as a CP1 candidate (lit scan returned 2026-05-19, see logs/houttuynia-cp1-dual-mechanism-lit-scan-2026-05-19.md). Beyond the C2/C4/C5 complement-targeting activity that anchors its CP0 standing, HCP and the purified 19.1 kDa HCPM fraction restore intestinal tight junction proteins (ZO-1, Occludin, Claudin-1) and suppress intestinal NLRP3 inflammasome / cleaved-caspase-1 / IL-1β / IL-18 in vivo (Li et al. 2025, PMC12254813, Chen Daofeng group, H1N1+MRSA coinfection model). The mechanism includes direct TLR4/MD-2 receptor engagement (Yu et al. 2026, PMC12937656, molecular docking + TAK-242 rescue) and gut-microbiota modulation (Chen et al. 2019, PMC7128561). Important structure-dependent caveat: purified 60 kDa HCP-2 homogalacturonan fraction is pro-inflammatory on naïve human PBMCs via TLR4 (Cheng et al. 2014, PMC7112369) — the in vivo anti-inflammatory phenotype emerges only in the context of pre-existing inflammation (LPS challenge, viral coinfection, MSU implied by mechanistic extrapolation). Structure-dependent directionality is real and parallel to but mechanistically distinct from the mushroom β-glucan Dectin-1 caveat: HCP works through TLR4 partial-agonism / hormetic competitive antagonism (NOT Dectin-1; different receptor class, no Dectin-1 cross-reactivity expected). Houttuynia is the first dual-CP0+CP1 dietary candidate in the OE corpus. Untested in MSU-NLRP3 (gout-specific) model — mechanistic extrapolation only; wet-lab MSU peritonitis test is the obvious next step. - Engineered surface-decay thread. comp-012 confirmed engineered DAF SCR1-4 (aa 35–285) is feasible in A. oryzae koji (LOW protease risk in shio-koji conditions per the comp-006 cascade; effective PDI load 2.4–4.8 per chaperone-orthogonal-stacking.md §3.5.3 with the corrected 8-disulfide count per UniProt P08174). H05 formalizes the engineered-DAF CP0 thesis.

The two threads target different geometric scales of complement activation: - Rosmarinic acid (dietary, gut-luminal and systemic post-absorption) — predicted operating site: fluid-phase C3 convertase + gut-luminal complement (where it would reduce C3b deposition substrate) - DAF SCR1-4 (engineered, luminal or systemic) — predicted operating site: MSU crystal surface (where it would accelerate decay of whatever C3b deposits)

If both predictions hold, the two interventions cover complementary steps of the CP0 cascade — fewer convertases assembling AND faster decay of those that do. The combined strategy would provide robust two-layer CP0 coverage without relying solely on avacopan (currently the only OE CP0 candidate with serious clinical-development infrastructure, but expensive and on-patent).

What this section does NOT claim (Pass 3 softening discipline preserved):

Rosmarinic acid does NOT "saturate fluid-phase and gut-luminal C3 convertase." comp-020 documented IC50 ~34 μM with a 44× assay-format spread and explicitly flagged dietary bioavailability + tissue occupancy as unresolved. Whether typical post-meal plasma + gut-luminal concentrations reach the IC50 range under either bound is unknown.
The two interventions are NOT asserted as "mechanistically additive." Both luminal-side DAF engagement geometry AND MSU-surface DAF accessibility are wet-lab unknowns (H05 Phase 2 killshots cover both). The combined-coverage claim is a testable hypothesis, not an asserted synergy.
No clinical effect-size prediction. Even if the mechanism prediction holds, downstream clinical SUA / IL-1β effect-sizes are gated by the same H08-class clinical-translation question that gates the gut-lumen sink thesis.

Computational gate — comp-029 returned YELLOW 2026-05-16. Two orthogonal Monte Carlo models (50,000 draws each) with explicit confidence bounds. Model 1: rosmarinic acid Hill inhibition with IC50 log-uniform [5 µM, 180 µM]; tested at fluid-phase systemic (5–100 nM, Baba 2004 Cmax anchor) AND gut-luminal (50–1,100 µM, Kang 2021 calculated intestinal concentration after 200 mg oral). Model 2: steady-state surface convertase model with intrinsic C4b2a t½ = 7.5 min, DAF max-acceleration cap 20×, three explicit MSU-surface accessibility priors α ∈ {0.05, 0.20, 0.80}. Combined via independent multiplicative composition. Verdict YELLOW at all three α priors — combined median 1.08–1.10× the better singleton (below the 1.5× GREEN threshold); combined 95% CI overlaps both singleton CIs. Both arms saturate individually at gut-luminal exposure, structurally capping multiplicative-composition gain near 1.1×.

Substantive reframe from comp-029 (load-bearing for §9.7): rosmarinic acid's CP0 effect is gut-luminal-transient, not systemic. At free plasma Cmax (~20 nM, Baba 2004), the systemic regime returned essentially 0% inhibition (median 0.0007) — free RA is ~1,700× below the central IC50. RA's CP0 leverage comes from the gut-luminal post-meal window (50–1,100 µM at the intestinal mucosa), not from systemic exposure. The dietary RA mechanism reframes as "gut-mucosal complement modulation during the post-meal window" rather than systemic CP0 coverage. The downstream effect would propagate via reduced C3b deposition substrate in the gut → less downstream complement amplification, not via direct plasma-phase fluid-complement inhibition.

Wet-lab follow-up (deferred per YELLOW): the §1.25 rosmarinic-acid co-treatment arm is NOT being added. Re-open condition: the §1.25 DAF SCR1-4 expression screen's functional readout already measures MSU-surface engagement as a side product — if §1.25 returns α ≥ 0.5, comp-029 re-runs to GREEN and a single fourth co-treatment condition (DAF SCR1-4 + 100 µM rosmarinic acid, same ELISA readout, one extra plate condition) gets added at marginal cost. The combined-strategy thesis is not refuted (comp-029 closed the RED interaction-blocker path); it's parked on a single load-bearing wet-lab measurement that §1.25 will deliver organically.

Cross-references: upstream-complement-modulator-sweep-computational.md (comp-018 dietary scan), upstream-complement-verification-rerun-computational.md (comp-020 verification re-run; the 44× IC50 spread caveat lives here), daf-cd55-scr14-truncated-computational.md (comp-012 engineering feasibility), chaperone-orthogonal-stacking.md §3.5.3 (effective PDI load), medicinal-mushroom-extract-sops.md (Tier 2 readout for rosmarinic acid potency in dietary sources), H05 — DAF SCR1-4 CP0 thesis.

9.8 Two-chassis, two-node CP0 coverage architecture — C1-INH (LBP-luminal) + DAF SCR1-4 (koji-secreted) (added 2026-05-16)¶

A second combined-CP0 strategy, distinct from §9.7's dietary + engineered composition: two engineered soluble complement regulators delivered across two independent chassis, each hitting a different cascade node.

C1-INH (SERPING1, UniProt P05155) via engineered LBP. comp-024 returned RED for complestatin and GREEN-provisional 0.774 for C1-INH-on-EcN in the LBP-luminal chassis. C1-INH inactivates C1r/C1s and MASP-2 at the classical/lectin pathway entry point, preventing C4b2a convertase formation upstream.
DAF SCR1-4 (aa 35–285, UniProt P08174) via engineered koji. comp-012 confirmed feasibility; H05 formalizes the thesis; §1.25 is the wet-lab gate. DAF accelerates decay of already-assembled C4b2a and C3bBb convertases at the MSU crystal surface.

Architecture-level point: C1-INH at classical/lectin entry prevents convertase formation; DAF at convertase decay disassembles those that form anyway. Two independent mechanisms at two different cascade points, delivered via two completely independent chassis (engineered EcN LBP vs engineered koji). Neither chassis competes for the other's production infrastructure; neither mechanism is redundant.

Relationship to §9.7. §9.7's rosmarinic-acid + DAF strategy is a dietary + engineered composition addressing fluid-phase + surface-decay. §9.8's C1-INH + DAF strategy is an engineered + engineered composition addressing entry + surface-decay. The two strategies are complementary, not competing — they cover different cascade physics with different delivery substrates. A future combined design could in principle stack both (rosmarinic acid + C1-INH-LBP + DAF-koji), though that's a Phase 2+ question; the immediate question is whether C1-INH survives the luminal protease environment.

Computational gate — comp-037 completed 2026-05-17 → MODERATE (kinetic-competition gated). The serpin-core construct (aa 123–500, mucin-truncated) returns three independent verdicts: strictly-degradative protease risk on the serpin body is LOW (0.1) after mucin truncation; the by-design exposed reactive-center loop (RCL, R466-T467) gives a RED (0.8) score reflecting the inhibitor mechanism, not body degradation; glycosylation feasibility is GREEN for luminal topology (N-glycans not required for catalytic suicide-substrate mechanism; plasma half-life concern moot for gut-luminal therapeutic). The combined verdict is MODERATE — the remaining risk is a wet-lab kinetic-competition question: does C1s/C1r/MASP-2 productively engage the RCL before DegP/elastase cleaves it unproductively? The two-chassis architecture is substantiated at the computational-gate level. C1-INH on EcN-LBP at classical/lectin entry + DAF SCR1-4 on koji at surface convertase decay — two independent mechanisms at two cascade points via two independent chassis. Wet-lab gates: RCL kinetic-competition assay (C1-INH) + §1.25 expression/activity screen (DAF SCR1-4). (Mechanistic Extrapolation; source: c1-inh-protease-stability-ecn-computational.md)

What this section does NOT claim:

C1-INH on EcN-LBP has NOT been wet-lab validated for luminal stability or complement-regulatory activity in the gut environment. The GREEN-provisional 0.774 comparator score from comp-024 is a feasibility prior, not an empirical result.
The C1-INH + DAF composition has NOT been wet-lab tested as a combined intervention. The mechanism-level coverage claim is a testable hypothesis, not an asserted synergy.
No clinical effect-size prediction. Even if both arms validate individually, downstream clinical CP0 coverage is gated by the same H08-class clinical-translation questions.

Cross-references: complestatin-bgc-lbp-feasibility-computational.md (comp-024 GREEN-provisional C1-INH), engineered-lbp-chassis.md (LBP chassis peer track), daf-cd55-scr14-truncated-computational.md (comp-012 DAF feasibility), H05 — DAF SCR1-4 CP0 thesis, chassis-pending-interventions.md (where C1-INH was previously named as an unscoped entry), validation-experiments.md §1.25 (DAF SCR1-4 wet-lab gate).

9.9 Dormant composition — C1-INH (LBP-luminal) + dietary rosmarinic acid (added 2026-05-19, Cluster G2 walkthrough)¶

A third combined-CP0 strategy sits between §9.7 (dietary + engineered surface-decay) and §9.8 (engineered + engineered entry + surface-decay): engineered C1-INH on EcN-LBP + dietary rosmarinic acid (no DAF SCR1-4). Mechanism layering at two distinct cascade nodes:

C1-INH (engineered, EcN-LBP) blocks classical and lectin pathway ENTRY — inactivates C1r / C1s / MASP-2 before C4b2a convertase formation. Per comp-037 the serpin-body protease risk is LOW after mucin truncation; remaining wet-lab gate is the RCL kinetic-competition assay (does C1s productively engage RCL before DegP/elastase cleaves it unproductively?).
Rosmarinic acid (dietary, no engineering) acts one step DOWNSTREAM — covalent C3b modification + C3 convertase inhibition. Per comp-018/020/029 the wet-lab status is gated on the 44× assay-format IC50 spread + gut-luminal PK uncertainty (whether the orally-bioavailable fraction reaches the relevant tissue compartment in active form).

Cascade-architecture logic: C1-INH prevents convertase formation at the classical/lectin entry point. Whatever C3b deposits anyway (via alternative-pathway tick-over or incomplete C1-INH coverage) gets blocked by dietary rosmarinic acid at the convertase-assembly step. Two independent failure modes, two independent cascade nodes, one dietary + one engineered. This composition has been hiding in plain sight because §9.7 paired rosmarinic acid with DAF (downstream surface-decay) and §9.8 paired C1-INH with DAF (downstream surface-decay); neither swapped DAF out for the dietary thread directly.

Why it's a DORMANT composition (not promoted to active comp-NNN):

Both component arms have unresolved wet-lab gates. The combined prediction would inherit BOTH uncertainties multiplicatively — meaning even a coherent mechanism story can't translate to a confident effect-size claim until at least one arm's gate clears. The discipline: do NOT queue a comp-NNN for this composition until one component's wet-lab gate returns positive data.

Reactivation conditions:

IF C1-INH RCL kinetic-competition assay returns positive → C1-INH arm de-risked → the rosmarinic-acid + C1-INH combined prediction becomes worth a comp-NNN.
IF rosmarinic acid gut-luminal PK (comp-029-style) returns adequate tissue exposure → rosmarinic-acid arm de-risked → same.
IF BOTH arms clear individually → the combined prediction becomes a wet-lab gate at validation-experiments §-tier in its own right.

What this section does NOT claim (Pass 3 epistemic discipline): - No asserted synergy between C1-INH and rosmarinic acid arms. - No clinical effect-size prediction — both arms' individual effect sizes remain wet-lab-unanchored. - This is mechanism-level cascade-architecture coverage, NOT a wet-lab-validated composition.

Cross-references: §9.7 (rosmarinic acid + DAF SCR1-4); §9.8 (C1-INH + DAF SCR1-4); c1-inh-protease-stability-ecn-computational.md (comp-037 C1-INH gate); upstream-complement-modulator-sweep-computational.md (comp-018 rosmarinic acid screen); upstream-complement-verification-rerun-computational.md (comp-020 rerun); rosmarinic-acid gut-luminal PK reframe per comp-029.

10. Natural-Product Modulators — What the Literature Actually Shows¶

10.1 ChEMBL survey of C5aR1 (CHEMBL2373)¶

ChEMBL contains thousands of bioactivity records on human C5aR1 (CHEMBL2373) — the unfiltered activity API returned ~4,873 total records as of 2026-04-28 (direct query), refreshed under the §1.21 computational scan. The exact count is filter-dependent — distinct-compound counts, pChEMBL cutoffs, and target-relationship filters all yield substantially smaller numbers, so an earlier 506 figure cited here was likely a filtered subset rather than total records. The qualitative claim that follows holds independent of the exact number. The potent-compound tail (pChEMBL ≥ 6) is dominated by synthetic peptides (cyclic hexapeptides in the PMX-53 / PMX-205 / C5a C-terminal mimic series, 1995-2006 BMCL/JMC papers) and avacopan-class allosteric small molecules. There are no natural products flagged natural_product=1 in the top C5aR1 antagonist rank list. Sub-μM natural product antagonists of human C5aR1 are effectively unreported in the curated database — confirmed on a fresh April 2026 query plus NPASS / LOTUS / Open Targets cross-checks (see §1.21 result section).

10.2 Flavonoids and complement — the weak, broad literature¶

A broad literature (PubMed, ~73 articles on "complement inhibitor natural product flavonoid") reports weak complement-pathway inhibition (CH50 or AP50 suppression at 50-500 μM) for many polyphenols. Representative findings:

Quercetin — reported CH50 inhibition IC50 ~100-200 μM (In Vitro, cell-free). Not C5aR1-specific; likely hitting multiple complement components (C1q, C3 convertase) non-selectively.
EGCG — CH50 inhibition in the same range; mechanism ambiguous
Resveratrol — weak
Baicalein, baicalin (Chinese skullcap) — some C3 convertase inhibition reported
Curcumin — CH50 inhibition; mechanism unclear

These are all 100-1000× weaker than synthetic C5aR1 antagonists (avacopan ~10 nM) and are broad-spectrum complement pathway modulators rather than specific C5a/C5aR1 drugs. At dietary doses they would not meaningfully plug CP0.

10.3 Omega-3 / SPM — indirect effects¶

EPA and DHA generate specialized pro-resolving mediators (RvE1, RvD1/D2, MaR1, PD1). These act via ALX/FPR2 and other receptors (see spm-resolution-pathway.md) — not directly at C5aR1. SPMs tilt the inflammatory phase toward resolution and partially suppress C5a-driven neutrophil chemotaxis by competing at the chemotactic level, but this is indirect and downstream. Not a CP0 therapy; a CP5b/CP6a resolver.

10.4 Vitamin D¶

VDR activation modestly suppresses complement component expression in some cell types, and vitamin D supplementation is associated with lower baseline CRP (which would reduce classical-pathway MSU activation per Wessig 2022). This is a weak, indirect effect — good for general health, irrelevant for acute CP0 blockade in a flare.

10.5 Traditional medicine candidates¶

Chinese medicine has multiple anti-gout herbal formulations (Baihu decoction, Simiao powder) without characterized complement mechanisms. Ayurvedic Boswellia / Tripterygium / Withania — no C5a-specific data. This is all hypothetical screening space.

10.6 Honest summary¶

Natural-product coverage of C5aR1 is weak to absent. The strongest C5aR1 antagonists are synthetic: avacopan (oral small molecule), PMX-53 (cyclic peptide, preclinical). Opening a natural-product screen against C5aR1 is a credible research move (§9.6) but should not be sold as "the plant medicine that replaces avacopan" — a pharma adjunct remains the honest stack position at CP0.

11. Clinical Biomarkers — Measuring CP0 in a Real Patient¶

11.1 Baseline complement panel (standard availability)¶

C3 and C4 (total protein, turbidimetry) — normal adult range C3 ~80-170 mg/dL, C4 ~15-45 mg/dL. Both can be low in active consumption (acute flare). Chronic elevation suggests acute-phase response without consumption; chronic low suggests persistent activation or congenital deficiency.
CH50 (total hemolytic complement, functional) — measures the ability of patient serum to lyse sensitized sheep erythrocytes via the classical pathway. Normal 30-75 CAE units. Low = consumption or deficiency. Does not distinguish which component.
AH50 (alternative pathway hemolytic) — analogous for alternative pathway.

These are standard hospital lab tests, inexpensive, same-day.

11.2 Split products and downstream (send-out / specialty)¶

Soluble C5a (+ desArg) — ELISA, e.g., Hycult or Quidel kits. Commercial availability at ARUP, Mayo Medical Labs, Quest (specific panels). Critical pre-analytic variable: sample must be collected on ice in EDTA, spun cold within 30 minutes, plasma aliquoted and frozen at -80°C. Warm transit generates spurious C5a in vitro from continued convertase activity. This is the single biggest reason specialty C5a assays misreport values.
Soluble C3a — similar kits, similar pre-analytic care.
sC5b-9 (shed MAC) — more stable than C5a (no receptor to bind, no carboxypeptidase to clip); easier to handle clinically. Elevated in chronic complement activation.
Bb (alternative pathway activation fragment) — cleavage product of Factor B; specifically reports alternative-pathway activation.
C4d, C3d/C3dg — activation split products of C4 and C3; used in transplant-rejection and lupus-nephritis workup; reports classical-pathway activation.

11.3 CRP as a CP0 stratifier¶

Given Wessig 2022 (CRP is the dominant classical-pathway initiator on MSU surfaces), baseline high-sensitivity CRP (hsCRP) is a plausible stratifier for "complement-primed" gout. Elevated hsCRP (>3 mg/L) in hyperuricemia likely predicts more vigorous C5a generation per flare. This is a testable hypothesis that could use existing gout-cohort biobanks.

11.4 Self-experiment application¶

Per self-experiment-protocol.md, optional CP0-relevant biomarkers to add during a flare window (with proper pre-analytics):

C3, C4, hsCRP (baseline and T0 / T+24 h of flare)
Plasma sC5b-9 (relatively easy handling, stable)
Plasma C5a (only if proper cold-chain is logistically achievable; otherwise the number is unreliable)
24-h urine with uric acid and a matched-timing hsCRP to see whether hyperuricemia-associated complement activation correlates with crystal-related flare physiology

This adds perhaps $150-400 per flare to the lab bill; scientific value is moderate (validates the mechanism in a specific individual) but not clinically actionable without comparative data.

12. Open Research Questions¶

Numbered so they can be lifted directly into open-questions.md:

Avacopan in gout — any clinical signal? Case reports of ANCA-vasculitis-plus-gout patients on avacopan; ad-hoc use in refractory gout. No registered trial as of April 2026. An investigator-initiated study (N=20-40, cross-over of flare frequency on/off avacopan) would be the shortest path to proof of concept.
Microbial C5aR1 antagonist peptide — is there a biosynthetic route in a GRAS organism (S. cerevisiae, A. oryzae, P. pastoris) to produce a PMX-53-like cyclic peptide with C5aR1 antagonist activity? Non-ribosomal peptide synthesis machinery in Aspergillus is extensive; cyclic hexapeptides are within range.
Natural-product screen against C5aR1 — systematic screen of the Open Enzyme supplement stack + dietary polyphenols against human C5aR1 using β-arrestin or calcium-flux functional readout. One 384-well plate, ~1 day assay time. Expected yield: most negative; any sub-μM hit is significant.
Is CP0 priming sufficient, or additive with LPS / TNFSF14? Experimental: human whole-blood MSU stimulation ± LPS ± C5aR1 antagonist ± TNFSF14 blockade; measure IL-1β, IL-6, neutrophil recruitment. Resolves the combination biology question §8.
Factor H variants and gout severity — UK Biobank / All of Us cross-tabulation of CFH rs1061170 × dietary polyphenol intake × incident gout M10.x. Status (2026-05-19): empirically untested; biobank feasibility documented in logs/cfh-y402h-dietary-cp0-biobank-mining-2026-05-19.md; closest analog (CFH × diet × AMD) points the opposite direction, mechanistic dissociation hypothesis (CP0 candidates bypass CFH-dependent regulation) is plausible but unverified. Operational path: collaboration with existing UKB gout-genetics groups, not solo OE application.
C5a vs. sC5b-9 in human gout synovial fluid — quantitative ratio of anaphylatoxin to MAC during an acute flare; identifies which effector dominates and informs C5aR1 (avacopan) vs. C5 (zilucoplan/eculizumab) target selection.
CRP-stratified gout flare intensity — prospective cohort of gout patients with baseline hsCRP and flare-phase C5a measurements; tests whether high-CRP patients have more vigorous complement priming per Wessig 2022.
Pegloticase immune-complex vasculitis and complement — a known pegloticase failure mode is ADA-driven immune complex vasculitis. Is complement activation the mediator? If yes, avacopan bridging could rescue pegloticase efficacy.
Uricase + avacopan combination in refractory gout — phase 2 concept: pegloticase / SEL-212 / PRX-115 + avacopan during crystal-dissolution window. Does avacopan reduce flare frequency during the danger window?
C5aR2 in gout — decoy or effector? Genetic (C5aR2⁻/⁻) and pharmacologic (selective C5aR2 ligands) dissection in human MSU-stimulated monocytes. Clarifies whether C5aR1-only drugs (avacopan) miss a significant signal.
Osteoclast C5aR1 and tophaceous bone erosion — does chronic complement activation drive bone damage in tophaceous disease? If yes, avacopan might be disease-modifying beyond flare prevention.
Microbial engineering angle — express a recombinant Factor H fragment or sCR1 (soluble complement receptor 1) in engineered koji for luminal complement regulation? Soluble CR1 is a complement regulator already in clinical trials (systemic form, TP10) — a gut-luminal version might modulate mucosal complement activation triggered by luminal crystals in severe hyperuricemia. Speculative; worth evaluating for feasibility.

Update (comp-006, 2026-05-05): AlphaFold pLDDT structural analysis of the DAF/CD55 soluble ectodomain (aa 35–353, P08174) under shio-koji conditions (17.5% NaCl, pH 4.5–5.0) returned HIGH (max risk score 0.388, NPr worst protease). The verdict is stalk-contingent: the Ser/Thr-rich stalk (aa 286–353, pLDDT 30–52) drives all 9 NPr-exposed and 48 ALP-exposed ectodomain sites. The SCR1–4 domains (aa 35–285, pLDDT 85–98) contribute zero exposed sites — they are structurally well-folded and largely buried. A stalk-truncated construct (aa 35–285, SCR1-4 only) would remove all exposed sites and is expected to return a LOW verdict (comp-007 is the logical follow-up). The HIGH verdict does not close the CD55 engineering thesis — it redirects it toward a stalk-truncated construct. See wiki/daf-cd55-protease-stability-computational.md for the full analysis. (Mechanistic Extrapolation; source: daf-cd55-protease-stability-computational.md, computational-experiments.md)

13. Sources (Annotated Bibliography)¶

Core mechanism (the CP0 canon)¶

Russell IJ, Mansen C, Kolb LM, Kolb WP. "Activation of the fifth component of human complement (C5) induced by monosodium urate crystals: C5 convertase assembly on the crystal surface." Clin Immunol Immunopathol 1982;24(2):239-50. DOI: 10.1016/0090-1229(82)90235-5. PMID: 6749358. The 1982 seed paper demonstrating direct C5 convertase assembly on MSU surfaces.
Doherty M, Richards N, Hornby J, Powell R. "Relation between synovial fluid C3 degradation products and local joint inflammation in rheumatoid arthritis, osteoarthritis, and crystal associated arthropathy." Ann Rheum Dis 1988;47(3):190-7. DOI: 10.1136/ard.47.3.190. PMID: 2833185. 288-sample synovial fluid study; acute pseudogout has strikingly elevated C3 activation.
An LL, Mehta P, Xu L, Turman S, Reimer T, Naiman B, Connor J, Sanjuan M, Kolbeck R, Fung M. "Complement C5a potentiates uric acid crystal-induced IL-1β production." Eur J Immunol 2014;44(12):3669-79. DOI: 10.1002/eji.201444560. PMID: 25229885. Human whole-blood and monocyte study; C5a + MSU is synergistic for IL-1β via C5aR1, K⁺ efflux, Ca²⁺, cathepsin B.
Cumpelik A, Ankli B, Zecher D, Schifferli JA. "Neutrophil microvesicles resolve gout by inhibiting C5a-mediated priming of the inflammasome." Ann Rheum Dis 2016;75(6):1236-45. DOI: 10.1136/annrheumdis-2015-207338. PMID: 26245757. C5a as dominant priming signal; PMN-Ecto / MerTK as endogenous resolution brake.
Khameneh HJ, Ho AWS, Laudisi F, Derks H, Kandasamy M, Sivasankar B, Teng GG, Mortellaro A. "C5a Regulates IL-1β Production and Leukocyte Recruitment in a Murine Model of Monosodium Urate Crystal-Induced Peritonitis." Front Pharmacol 2017;8:10. DOI: 10.3389/fphar.2017.00010. PMID: 28167912. Murine validation; C5a via ROS, not transcription; C5aR antagonism ameliorates peritonitis.
Wessig AK, Hoffmeister L, Klingberg A, Alberts A, Pich A, Brand K, Witte T, Neumann K. "Natural antibodies and CRP drive anaphylatoxin production by urate crystals." Sci Rep 2022;12(1):4483. DOI: 10.1038/s41598-022-08311-z. PMID: 35296708. IgM and CRP are both required for efficient classical-pathway MSU activation; CRP is the dominant C5a generator.

Receptor structure and function¶

Liu H, Kim HR, Deepak RNVK, Wang L, Chung KY, Fan H, Wei Z, Zhang C. "Orthosteric and allosteric action of the C5a receptor antagonists." Nat Struct Mol Biol 2018;25(6):472-481. DOI: 10.1038/s41594-018-0067-z. PMID: 29867214. C5aR1 crystal structures with PMX-53 (orthosteric) + avacopan (allosteric); orthosteric / allosteric dual-site druggability.

Clinical and therapeutic¶

Jayne DRW, Merkel PA, Schall TJ, Bekker P (for the ADVOCATE Study Group). "Avacopan for the Treatment of ANCA-Associated Vasculitis." N Engl J Med 2021;384(7):599-609. DOI: 10.1056/NEJMoa2023386. PMID: 33596356. Phase 3 ADVOCATE trial; basis for FDA 2021 approval.
Vlaar APJ, Witzenrath M, van Paassen P, et al. "Anti-C5a antibody (vilobelimab) therapy for critically ill, invasively mechanically ventilated patients with COVID-19 (PANAMO): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial." Lancet Respir Med 2022;10(12):1137-1146. DOI: 10.1016/S2213-2600(22)00297-1. PMID: 36087611. Vilobelimab Phase 3; basis for FDA EUA 2023.
Vlaar APJ, de Bruin S, Busch M, et al. "Anti-C5a antibody IFX-1 (vilobelimab) treatment versus best supportive care for patients with severe COVID-19 (PANAMO): an exploratory, open-label, phase 2 randomised controlled trial." Lancet Rheumatol 2020;2(12):e764-e773. DOI: 10.1016/S2665-9913(20)30341-6. PMID: 33015643.
Lim EHT, Vlaar APJ, de Bruin S, et al. "Pharmacokinetic analysis of vilobelimab, anaphylatoxin C5a and antidrug antibodies in PANAMO: a phase 3 study in critically ill, invasively mechanically ventilated COVID-19 patients." Intensive Care Med Exp 2023;11(1):37. DOI: 10.1186/s40635-023-00520-8. PMID: 37332066. C5a dropped 87% by day 8; no ADAs; PK characterization.
Howard JF Jr, Bresch S, Genge A, et al. "Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study." Lancet Neurol 2023;22(5):395-406. DOI: 10.1016/S1474-4422(23)00080-7. PMID: 37059508. RAISE Phase 3; FDA 2023 approval.
de la Borderie G, Chimits D, Boroojerdi B, et al. "Maintenance of zilucoplan efficacy in patients with generalised myasthenia gravis up to 24 weeks: a model-informed analysis." Ther Adv Neurol Disord 2024;17:17562864241279125. DOI: 10.1177/17562864241279125. PMID: 39314260. Efficacy durability through 24 weeks.

Gout context and pipeline¶

Zaninelli TH, Fattori V, Verri WA Jr. "Harnessing lipid mediators and immune cells to treat gouty arthritis." Expert Opin Ther Targets 2023;27(8):751-766. DOI: 10.1080/14728222.2023.2247559. PMID: 37651647. Review naming complement arm as an under-exploited gout target.
Schauer C, Janko C, Munoz LE, et al. "Aggregated neutrophil extracellular traps limit inflammation by degrading cytokines and chemokines." Nat Med 2014;20(5):511-7. DOI: 10.1038/nm.3547. PMID: 24784231. NET degradation of C5a and IL-1β as endogenous resolution mechanism; relevant to CP6a.

Natural antibody / CRP connection¶

(Wessig 2022 — see entry 6; central to the classical-pathway initiation story.)

Regulatory labels (non-PubMed primary sources)¶

Avacopan (Tavneos) FDA label. Amgen / ChemoCentryx. Approval October 2021 for ANCA-associated vasculitis. FDA label.
Vilobelimab (Gohibic) FDA EUA. InflaRx. EUA April 2023 for severe COVID-19. FDA EUA letter.
Zilucoplan (Zilbrysq) FDA label. UCB. Approval October 2023 for generalized myasthenia gravis.
Eculizumab (Soliris) FDA label. Alexion / AstraZeneca. First approved March 2007 for PNH. FDA label.
Ravulizumab (Ultomiris) FDA label. Alexion / AstraZeneca. First approved December 2018 for PNH.
Iptacopan (Fabhalta) FDA label. Novartis. First approved December 2023 for PNH; IgA nephropathy and C3 glomerulopathy approvals 2024. FDA label.

ChEMBL cross-references¶

C5aR1 target: CHEMBL2373 (UniProt P21730)
C5aR2 subunit within complex [CHEMBL4523605]
Avacopan: CHEMBL3989871 (first approval 2021, oral)
Vilobelimab: CHEMBL2109636
Zilucoplan: CHEMBL4298207 / CHEMBL5315048 (sodium salt, approved 2023)
Eculizumab: CHEMBL1201828 (first approval 2007, IV)
Ravulizumab: CHEMBL3989986 (first approval 2018, IV)
Iptacopan: CHEMBL4594448 / CHEMBL5095401 (HCl salt, first approval 2023, oral)
PMX-53: CHEMBL62201 (IC50 60 nM on human PMN C5aR1 radioligand binding, pChEMBL 7.22, J Med Chem 1999)

This page is part of the Open Enzyme research library. Phase 0 — Research and Design. No claims in this document constitute medical advice. All therapeutic discussion is research-stage and, where applicable, off-label.